Ohr Pharmaceutical To Present At The 35th Annual Cowen and Company Health Care Conference
NEW YORK, March 3, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive Officer, will present a corporate overview and business update at the 35th Annual Cowen & Company Health Care Conference.
| Details of the Presentations: | |
| Title: | 35th Annual Cowen & Company Health Care Conference |
| Date: | Wednesday, March 4 |
| Time: | 9:20am Eastern |
| Location: | Orleans Room, Boston Marriott Copley Place |
| Webcast: | http://wsw.com/webcast/cowen22/ohrp |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead product, Squalamine, is currently being studied as an eye drop formulation (OHR-102) in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. The company also has a research agreement with Alcon on a sustained release program. Additional information on the company may be found at www.ohrpharmaceutical.com.
CONTACT: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 ir@ohrpharmaceutical.com LifeSci Advisors, LLC Michael Wood 646-597-6983 mwood@lifesciadvisors.comHelp employers find you! Check out all the jobs and post your resume.